Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 5/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31183075 | 1.00 | CA9 (0.38) | CA9PNMTTDP2NOTUMPTPN5 | |
| SCHEMBL30934684 | 0.84 | PNMT (0.38) | CA9PNMTTDP2PTPN5PDE2A | |
| SCHEMBL20274233 | 0.84 | PNMT (0.38) | CA9PNMTTDP2PTPN5PDE2A | |
| SCHEMBL15590222 | 0.82 | AR (0.39) | — | |
| SCHEMBL8110125 | 0.81 | NOTUM (0.36) | PNMTTDP2NOTUMPTPN5PDE2A | |
| SCHEMBL6939064 | 0.80 | ALDH1A1 (0.38) | CA9 | |
| SCHEMBL15582358 | 0.79 | HSD11B1 (0.36) | — | |
| SCHEMBL4827450 | 0.77 | FFAR1 (0.46) | — | |
| SCHEMBL34474640 | 0.72 | CA1 (0.33) | CA9NOTUM | |
| SCHEMBL8031077 | 0.72 | CA1 (0.33) | CA9NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250154172-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-117024483-A | Metallocene complex and application thereof | 海南贝欧亿科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-9067921-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067921-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| CN-103012374-B | Piperizinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORP | 2015-05-20 | — | — | CN | disclosed |
| US-7678798-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| EP-1734966-A4 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| CN-1968698-A | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE SAN DIEGO INC (US) | 2007-05-23 | — | — | CN | disclosed |
| EP-1734966-A2 | PIPERIZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | Incyte Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005101838-A2 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| US-5292736-A | Morpholinoalkylindenes as antiglaucoma agents | STERLING WINTHROP INC. (US) | 1994-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | CA9 2656/4885PNMT 815/4885TDP2 537/4885 |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | CA9 4085/4885PNMT 4874/4885TDP2 3296/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | CA9 3023/4885PNMT 217/4885TDP2 162/4885 |
| US-20250154172-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | CA9 3044/4885PNMT 246/4885TDP2 189/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | CA9 3023/4885PNMT 217/4885TDP2 162/4885 |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | CCR5, CCR2, CXCR5 | CA9 4565/4885PNMT 2038/4885TDP2 4255/4885 |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | CA9 4565/4885PNMT 2038/4885TDP2 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.